← Back to patent-cliff list
阿托伐他汀/氢氯噻嗪/阿司匹林/依那普利
Tier C — Watch / tradeAtorvastatin/Hydrochlorothiazide/Aspirin/Enalapril
Alborz Darou Pharmaceutical
Originator
2018
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Thiazide-sensitive sodium-chloride cotransporter、ACE、HMGCR、COXs
Brand：Polypill-E、PolyPill 4-1
Indications (approved)：心脏和血管疾病
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril?
Approved indications include: 心脏和血管疾病.
When does the Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril patent expire?
No public expiry year is available for Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril yet; this page updates once verified.
How do I get a quote for Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24